Sanofi-Aventis suffers as data again link Lantus with cancer risk
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's blockbuster long-acting insulin analogue Lantus (insulin glargine) is associated with an increased cancer incidence, concludes a recent research article published in Diabetes Care. The charge comes nearly exactly one year since the French drug firm found itself defending against the same charge, made in series of Diabetologia articles (scripnews.com, 30 June 2009).